SCYNEXIS Announces Its Phase 1 Trial Of Intravenous Formulation Of SCY-247 To Treat Invasive Fungal Infections Showed Intravenous Doses Of 50 Mg Or Higher Achieved Exposures At Or Above Target Identified In Murine Models Of Invasive Candidiasis

Benzinga

2026.10.22 12:03 (GMT+0)

Abrir em Benzinga